exRNAdisease

Entry Detail

---



General Information

Database ID: exR0087655 RNA Name: hsa-miR-1244 RNA Type: miRNA Chromosome: chr2 Starnd: + Coordinate: Start Site(bp): 231713368 End Site(bp): 231713393 External Links: hsa-miR-1244

Disease Information

Disease Name: Breast Cancer Disease Category: Cancers MeSH ID: D001943 Type: Neoplasms/Breast Neoplasms Alias: Breast Neoplasms//Breast Neoplasm//Neoplasm, Breast//Breast Tumors//Breast Tumor//Tumor, Breast//Tumors, Breast//Neoplasms, Breast//Breast Cancer//Cancer, Breast//Mammary Cancer//Cancer, Mammary//Cancers, Mammary//Mammary Cancers//Malignant Neoplasm of Breast//Breast Malignant Neoplasm//Breast Malignant Neoplasms//Malignant Tumor of Breast//Breast Malignant Tumor//Breast Malignant Tumors//Cancer of Breast//Cancer of the Breast//Mammary Carcinoma, Human//Carcinoma, Human Mammary//Carcinomas, Human Mammary//Human Mammary Carcinomas//Mammary Carcinomas, Human//Human Mammary Carcinoma//Mammary Neoplasms, Human//Human Mammary Neoplasm//Human Mammary Neoplasms//Neoplasm, Human Mammary//Neoplasms, Human Mammary//Mammary Neoplasm, Human//Breast Carcinoma//Breast Carcinomas//Carcinoma, Breast//Carcinomas, Breast

Expression Detail

GEO ID: GSE101841 Description: Serum microRNA profile of Her2 positive metastatic breast cancer patients Experimental Design: Trastuzumab therapy Case Disease Type: Breast Cancer Case Disease SubType: HER2 positive metastatic breast cancer Case Sample: Breast Cancer Trastuzumab resistant Control Sample: Trastuzumab sensitive Number of Case: 42 Number of Control: 61 Number of Samples: 103

Regulatory Relationship

mRNA targets: Gene Symbol Chromosome Start Site(bp) End Site(bp) Strand RHOA chr3 49359145 49412998 - CPNE3 chr8 86514435 86561498 + KIAA1191 chr5 176346062 176361807 - ZMYM4 chr1 35268709 35422058 + CCT2 chr12 69585426 69601570 + AL590764.2 chrX 71103987 71111575 - RPS5 chr19 58386400 58394806 + UBA2 chr19 34428352 34471251 + CDC42EP3 chr2 37641882 37738468 - EEF1G chr11 62559596 62574086 - GAK chr4 849276 932373 - SPIN1 chr9 88388430 88478694 + ERLIN1 chr10 100150094 100186033 - MT-CO3 chrMT 9207 9990 + HNRNPU chr1 244840638 244864560 - TOLLIP chr11 1274371 1309654 - MLF2 chr12 6747996 6767475 - CCDC18 chr1 93179919 93278730 + MBD3 chr19 1573596 1592865 - RPS2 chr16 1962058 1964841 - PTMA chr2 231706895 231713541 + UBC chr12 124911604 124917368 - OAS2 chr12 112978395 113011723 + APELA chr4 164877178 164898965 + SLC7A1 chr13 29509414 29595688 - ARHGDIB chr12 14942031 14961728 - ARMT1 chr6 151452258 151470101 + AP002990.1 chr11 62559603 62591531 - B2M chr15 44711487 44718877 + RFWD3 chr16 74621399 74666877 - miRNA targets: NA circRNA targets: NA lncRNA targets: NA Display:

Experiment Detail

GEO ID: GSE101841 Sample Source: Blood Source Fraction: Serum Platform: GPL23138 Method: Microarray Num of detected RNA Type: 1 Num of detected RNAs of this Type: 1808 Sample treatment protocol: NA RNA Extract protocol: Total RNA was extracted from 103 samples with the Plasma RNA Purification Mini Kit (51000, NorgenBiotek Corporation, Canada), following manufacturer's instructions. RNA library preparation protocol: Total RNA extracted from 600ul serum was employed with 100 nmol/L of pCp-DY647 and 15 Units of T4 RNA ligase in a total reaction volume of 20 ul at 16°C overnight.

Reference

PMID: 29691399 Title: A serum microRNA signature predicts trastuzumab benefit in HER2-positive metastatic breast cancer patients. Author: Li H, Liu J, Chen J, Wang H, Yang L, Chen F, Fan S, Wang J, Shao B, Yin D, Zeng M, Li M, Li J, Su F, Liu Q, Yao H, Su S, Song E Journal: Nat Commun. 2018 Apr 24;9(1):1614. Description: MicroRNAs (miRNAs) have been used to predict therapeutic effects for various cancers, but whether miRNAs can serve as biomarkers for HER2+ metastatic breast cancer (MBC) patients remains unclear.